.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,994,409

« Back to Dashboard
Patent 5,994,409 protects ETHYOL and is included in one NDA. There has been one Paragraph IV challenge on Ethyol.

This patent has fourteen patent family members in twelve countries.

Summary for Patent: 5,994,409

Title: Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
Abstract:The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.
Inventor(s): Stogniew; Martin (Blue Bell, PA), Alberts; David S. (Tucson, AZ), Kaplan; Edward H. (Skokie, IL)
Assignee: U.S. Bioscience, Inc. (West Conshohocken, PA) The Arizona Board of Regents on behalf of the University of Arizona (Tuscon, AZ)
Application Number:08/987,550
Patent Claim Types:
see list of patent claims
Use; Delivery;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 11th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Clinigen Hlthcare
ETHYOL
amifostine
INJECTABLE;INJECTION020221-002Sep 10, 1999DISCNNo5,994,409► subscribe METHODS FOR USING THE DRUG PRODUCT
Clinigen Hlthcare
ETHYOL
amifostine
INJECTABLE;INJECTION020221-001Dec 8, 1995RXYes5,994,409► subscribe METHODS FOR USING THE DRUG PRODUCT
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,994,409

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,105,575Methods for the treatment of neuro- disorders using aminothiol compounds► subscribe
6,586,476 Methods for the treatment of nephro-disorders using aminothiol compounds► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,994,409

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria326956► subscribe
Australia1718499► subscribe
Australia739068► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc